IMAX Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
IMAX wird ein jährliches Gewinn- und Umsatzwachstum von 21.6% bzw. 6.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 27.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16.9% betragen.
Wichtige Informationen
21.6%
Wachstumsrate der Gewinne
27.51%
EPS-Wachstumsrate
| Entertainment Gewinnwachstum | 24.0% |
| Wachstumsrate der Einnahmen | 6.3% |
| Zukünftige Eigenkapitalrendite | 16.86% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 09 Sep 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrative-Update • Sep 07
IMAX: Premium Formats And Network Expansion Will Shape Balanced Odyssey-Led Outlook
IMAX's analyst fair value estimate has shifted from $52.73 to $55.65 as analysts lift price targets into the $60 to $65 range, citing stronger box office contributions from The Odyssey, higher Q3 revenue expectations, and ongoing network growth. Analyst Commentary Recent commentary on IMAX is skewed toward optimism, with many bullish analysts lifting price targets into the $60 to $65 range, while a smaller group urges more caution.Narrative-Update • Aug 24
IMAX: Premium Formats And Network Expansion Will Underpin Balanced Future Outlook
Analysts have nudged their fair value estimate for IMAX higher, with the updated target of $52.73 from $50.27. This reflects recent price target increases tied to stronger Q3 box office expectations around "The Odyssey," ongoing momentum in premium formats, and anticipated margin and cash flow benefits from network expansion.Narrative-Update • Aug 07
IMAX: Premium Formats And Sale Optionality Will Shape Balanced Future Outlook
Analysts have raised the IMAX fair value estimate from about $46.82 to roughly $50.27, citing higher Street price targets clustered around $50 to $54. They highlight stronger Q2 results, growing consumer preference for IMAX screenings, and continued network expansion supported by titles like The Odyssey.
Narrative-Update • Jul 24
IMAX: Filmed For Large Format Slate And Potential Sale Will Support Upside
Analysts have raised the updated fair value estimate for IMAX from $55.99 to $59.72, citing higher Street price targets supported by a Q2 earnings beat, strong performance from "The Odyssey," increasing demand for filmed-for-IMAX content, and ongoing global system installations. Analyst Commentary Bullish analysts covering IMAX are largely framing the recent Q2 earnings beat and the success of "The Odyssey" as key supports for higher valuation ranges, with a series of price target increases reflecting confidence in both execution and growth initiatives.Seeking Alpha • Jul 24
IMAX Corporation: Box Office Expansion Drives The Investment
Summary IMAX Corporation reported solid Q2 results, driven by higher system installations in theaters. The short-term forward outlook is driven by a favorable film slate, notably including The Odyssey, filmed fully on IMAX 70mm film cameras. IMAX should continue to gain box office market share in upcoming years, driven by filmmaker interest and theater network expansion. After a strong stock rally, IMAX stock's base scenario growth potential is already priced in. I estimate a fair value of $43.9. Read the full article on Seeking AlphaAnalyseartikel • Jun 18
IMAX (IMAX) Stock Could Be 5.3% Undervalued After Disclosure Day Opening Weekend
IMAX (IMAX) stock moved after Universal’s Disclosure Day delivered a robust opening weekend, with IMAX premium screens capturing nearly 15% of the film’s US$93.9 million global box office. See our latest analysis for IMAX. Beyond this weekend’s box office boost, IMAX’s recent share price momentum has been building, with a 30 day share price return of 33.97% and a 1 year total shareholder return of 51.82% reflecting how investors are reassessing both growth potential and risk. If this kind of...Narrative-Update • Jun 15
IMAX: Film Slate Management And Potential Sale Will Support Future Upside
The analyst price target for IMAX has increased from $47.00 to about $56.00, as analysts point to stronger margin potential, active film slate management and renewed interest following reports that the company is exploring a possible sale. Analyst Commentary Recent research has centered on how the current film slate, margin potential and potential corporate activity could affect the stock's valuation.Narrative-Update • Jun 01
IMAX: Premium Formats And Potential Sale Interest Will Drive Future Upside
Analysts have nudged their implied fair value estimate for IMAX higher from about $45.27 to $46.82, citing expectations for stronger revenue growth, higher forecast margins, and recent Street research that highlights potential corporate interest in the company. Analyst Commentary Recent Street research around IMAX reflects an active debate on valuation, execution, and potential corporate interest in the company.
Narrative-Update • May 02
IMAX: Global Premium Footprint Expansion Will Shape Future Earnings Power
The analyst price target for IMAX edges higher to about $41.09 from $41.00 as analysts incorporate mixed target moves across firms, modest adjustments to revenue growth and margin assumptions, and slightly higher future P/E expectations. Analyst Commentary Recent Street research on IMAX presents a mixed picture, with several firms lifting price targets while a smaller group trims expectations and highlights areas of risk.Narrative-Update • Apr 18
IMAX: Premium Theatrical Formats And Strong Box Office Will Drive Future Upside
The IMAX analyst price target edges higher to about $45.27 from $45.00, as analysts factor in recent target raises tied to strong Q4 results, higher box office activity, robust system installs, and expectations for continued importance within the global theatrical ecosystem. Analyst Commentary Recent Street research on IMAX clusters around higher price targets and generally positive reactions to the latest quarterly results, box office trends, and system installation activity.Narrative-Update • Apr 04
IMAX: Future Earnings Base And Global Footprint Frame Balanced Opportunity And Risk
Narrative Update: IMAX Analyst Price Target Shift The analyst price target for IMAX has moved to $41.00. Analysts cite record share gains, accelerating international expansion, strong Q4 and full-year revenue and margins, and continued outperformance versus consensus as key factors influencing their updated views.Narrative-Update • Mar 21
IMAX: Record Box Office And Premium Format Position Will Support Future Upside
The analyst price target for IMAX is raised by about $1 to $45.00, as analysts factor in higher margin expectations, a lower assumed future P/E multiple, and recent research citing strong quarterly results, record box office driven revenue, and a stronger position in the global theatrical ecosystem. Analyst Commentary Recent research updates show a cluster of target price increases for IMAX, with analysts reacting to reported results, box office trends, and the company’s role in premium theatrical formats.Narrative-Update • Mar 06
IMAX: Future Earnings Base And International Footprint Suggest Balanced Opportunity And Risk
The Analyst Price Target for IMAX has increased from $22.04 to $41.00. This reflects analysts' views that recent record revenue, strong margins, higher box office activity and an expanding international footprint support a higher assumed profit margin and P/E multiple in updated models.Narrative-Update • Feb 20
IMAX: Live Sports And Content Partnerships Will Support Future Upside
Analysts have maintained their $47.00 price target on IMAX, citing updated assumptions around discount rate, revenue growth, profit margin, and a higher future P/E multiple. They also highlight broader sector risks such as high development costs, dependence on single assets, and limited near term catalysts in comparable coverage.Narrative-Update • Feb 05
IMAX: Future Slate And Execution Will Support Expanded Premium Format Opportunities
Analysts have inched their price target for IMAX higher to approximately US$44.09 from about US$43.73, reflecting updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary Analysts have updated their IMAX models around revenue, margins and future P/E levels, which feeds directly into the small lift in the price target to about US$44.09.Narrative-Update • Jan 22
IMAX: Future Slate And Profit Execution Will Support Measured Upside Potential
Analysts have lifted their IMAX fair value estimate from about US$38.81 to roughly US$43.73 per share, citing updated assumptions for revenue growth, profit margins and a lower future P/E that together support a higher price target. Analyst Commentary Analysts reviewing IMAX after the updated fair value estimate are split between what could support the higher valuation and what might limit upside if execution falls short.Narrative-Update • Jan 08
IMAX: Premium Screens And Local Language Hits Will Support Future Upside
Analysts have raised their price target on IMAX to $40 from $36, citing record Q3 global box office results, an increasing market share, strong local language titles, and faster-than-expected network expansion in markets with above-average revenue per screen. Analyst Commentary Bullish analysts point to IMAX's recent record Q3 global box office results and its second highest quarterly gross as key supports for their updated views, highlighting what they see as solid execution across the business.Narrative-Update • Dec 21
IMAX: Expanding Premium Network Will Drive Stronger Box Office Performance
Analysts have lifted their price target on IMAX to approximately $47 from about $38, citing accelerating network expansion into higher revenue markets, record and resilient box office performance, and an expectation for stronger, more profitable growth that, in their view, supports a lower forward earnings multiple versus historical levels. Analyst Commentary Bullish analysts have recently highlighted IMAX as one of the stronger execution stories in the theatrical ecosystem, pointing to a mix of box office outperformance, premium market exposure, and disciplined capital deployment as key supports for higher valuation.Narrative-Update • Dec 07
IMAX: Future Slate And Premium Screen Expansion Will Drive Measured Performance
We raise our IMAX price target to approximately $39 from about $37, as analysts highlight record Q3 box office performance, accelerating high value screen expansion, and a robust Q4 film slate that together support modestly stronger growth and valuation assumptions. Analyst Commentary Recent Street commentary on IMAX has tilted clearly positive, with multiple firms raising price targets in response to stronger than expected operating trends and an improving growth outlook.Narrative-Update • Nov 22
IMAX: Future Box Office Releases And Network Expansion Will Shape Performance
IMAX's analyst price target has increased significantly, rising from $36 to $37 per share to $40 to $42 per share, as analysts cite strong quarterly box office results, ongoing network expansion, and promising upcoming film releases as key drivers of growth. Analyst Commentary Recent updates from street research provide insights into the positive momentum behind IMAX's upgraded price targets, as well as areas of continued scrutiny among analysts.Narrative-Update • Nov 01
IMAX: Accelerating Network Expansion Will Drive Global Box Office Performance
The analyst consensus price target for IMAX has increased from approximately $36.45 to $37.18. Analysts highlight strong box office performance and accelerating network expansion as key drivers for the upward revision.Narrative-Update • Oct 18
North America And Japan Installations Will Strengthen Premium Entertainment
Analysts have raised their price target for IMAX from approximately $34.36 to $36.45. They cite stronger box office performance, accelerating network expansion, and improved margins as key factors supporting the higher valuation.Narrative-Update • Oct 04
North America And Japan Installations Will Strengthen Premium Entertainment
IMAX's analyst price target has been raised from $31 to $38, reflecting higher expected margins and valuation multiples according to analysts. Analyst Commentary Analyst sentiment toward IMAX has recently shifted, leading to an upward revision of the company's price target.Analyseartikel • Sep 09
Earnings Tell The Story For IMAX Corporation (NYSE:IMAX) As Its Stock Soars 25%
IMAX Corporation ( NYSE:IMAX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Analyseartikel • Aug 04
Is Now An Opportune Moment To Examine IMAX Corporation (NYSE:IMAX)?
IMAX Corporation ( NYSE:IMAX ), is not the largest company out there, but it received a lot of attention from a...Analyseartikel • Jun 13
An Intrinsic Calculation For IMAX Corporation (NYSE:IMAX) Suggests It's 32% Undervalued
Key Insights IMAX's estimated fair value is US$42.15 based on 2 Stage Free Cash Flow to Equity Current share price of...Analyseartikel • May 17
Market Participants Recognise IMAX Corporation's (NYSE:IMAX) Earnings Pushing Shares 25% Higher
IMAX Corporation ( NYSE:IMAX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Analyseartikel • May 02
IMAX's (NYSE:IMAX) Soft Earnings Are Actually Better Than They Appear
Shareholders appeared unconcerned with IMAX Corporation's ( NYSE:IMAX ) lackluster earnings report last week. We think...Analyseartikel • Apr 19
Should You Investigate IMAX Corporation (NYSE:IMAX) At US$22.45?
While IMAX Corporation ( NYSE:IMAX ) might not have the largest market cap around , it saw significant share price...Analyseartikel • Apr 04
Here's What's Concerning About IMAX's (NYSE:IMAX) Returns On Capital
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Analyseartikel • Mar 15
We Think IMAX (NYSE:IMAX) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Mar 09
IMAX Corporation: Unlocking Asymmetric Gains In Premium Cinema
Summary IMAX remains the leading choice for premium cinema experiences, generating outsized box office returns despite a small footprint of 1% of total screens. The company’s success in China is encouraging, but future box office results may be dampened due to a lack of new local content. IMAX’s global expansion in local language partnerships could face higher costs and challenges adapting to diverse filmmaking workflows. While financially recovered from the pandemic, IMAX’s growth trajectory appears plateaued, with flat revenue and cash flow projections. Given the overvaluation of IMAX stock, investors should hold and wait for a significant price retracement before considering entry. Read the full article on Seeking AlphaAnalyseartikel • Jan 08
Is Now The Time To Look At Buying IMAX Corporation (NYSE:IMAX)?
While IMAX Corporation ( NYSE:IMAX ) might not have the largest market cap around , it led the NYSE gainers with a...Seeking Alpha • Dec 24
IMAX Corporation: Overseas Growth Opportunities
Summary IMAX Corporation's stock has surged 60% since its June lows, but there has been a notable uptick in insider selling in December. IMAX Corporation has considerable long-term growth opportunities and should benefit from an expected well-received movie slate in 2025. An analysis of IMAX Corporation follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Dec 10
IMAX (NYSE:IMAX) Has Some Difficulty Using Its Capital Effectively
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Analyseartikel • Nov 23
IMAX Corporation (NYSE:IMAX) Shares Could Be 44% Below Their Intrinsic Value Estimate
Key Insights IMAX's estimated fair value is US$45.02 based on 2 Stage Free Cash Flow to Equity IMAX's US$25.19 share...Analyseartikel • Nov 07
After Leaping 26% IMAX Corporation (NYSE:IMAX) Shares Are Not Flying Under The Radar
The IMAX Corporation ( NYSE:IMAX ) share price has done very well over the last month, posting an excellent gain of...Analyseartikel • Oct 31
Here's Why IMAX (NYSE:IMAX) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Oct 13
If EPS Growth Is Important To You, IMAX (NYSE:IMAX) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 501 | 95 | 151 | 182 | 8 |
| 12/31/2027 | 481 | 96 | 130 | 174 | 11 |
| 12/31/2026 | 461 | 82 | 109 | 144 | 11 |
| 6/30/2026 | 416 | 41 | 100 | 133 | N/A |
| 3/31/2026 | 405 | 37 | 90 | 124 | N/A |
| 12/31/2025 | 410 | 35 | 85 | 127 | N/A |
| 9/30/2025 | 378 | 40 | 64 | 109 | N/A |
| 6/30/2025 | 362 | 33 | 29 | 77 | N/A |
| 3/31/2025 | 360 | 25 | 40 | 89 | N/A |
| 12/31/2024 | 352 | 26 | 30 | 71 | N/A |
| 9/30/2024 | 346 | 23 | 19 | 63 | N/A |
| 6/30/2024 | 358 | 21 | 17 | 57 | N/A |
| 3/31/2024 | 367 | 26 | -9 | 26 | N/A |
| 12/31/2023 | 375 | 25 | 26 | 59 | N/A |
| 9/30/2023 | 387 | 25 | 43 | 71 | N/A |
| 6/30/2023 | 352 | 4 | 21 | 48 | N/A |
| 3/31/2023 | 328 | -7 | 11 | 42 | N/A |
| 12/31/2022 | 301 | -23 | -15 | 17 | N/A |
| 9/30/2022 | 311 | -15 | -4 | 26 | N/A |
| 6/30/2022 | 299 | -15 | -7 | 18 | N/A |
| 3/31/2022 | 276 | -21 | -7 | 13 | N/A |
| 12/31/2021 | 255 | -22 | -12 | 6 | N/A |
| 9/30/2021 | 202 | -54 | -25 | -12 | N/A |
| 6/30/2021 | 183 | -93 | -29 | -19 | N/A |
| 3/31/2021 | 141 | -109 | -50 | -40 | N/A |
| 12/31/2020 | 137 | -144 | -32 | -23 | N/A |
| 9/30/2020 | 205 | -104 | -28 | -8 | N/A |
| 6/30/2020 | 254 | -48 | -8 | 21 | N/A |
| 3/31/2020 | 350 | -11 | N/A | 97 | N/A |
| 12/31/2019 | 396 | 47 | N/A | 90 | N/A |
| 9/30/2019 | 380 | 30 | N/A | 109 | N/A |
| 6/30/2019 | 376 | 26 | N/A | 112 | N/A |
| 3/31/2019 | 370 | 23 | N/A | 94 | N/A |
| 12/31/2018 | 374 | 23 | N/A | 110 | N/A |
| 9/30/2018 | 391 | 26 | N/A | 90 | N/A |
| 6/30/2018 | 408 | 20 | N/A | 95 | N/A |
| 3/31/2018 | 397 | 11 | N/A | 101 | N/A |
| 12/31/2017 | 381 | 2 | N/A | 85 | N/A |
| 9/30/2017 | 362 | 6 | N/A | 96 | N/A |
| 6/30/2017 | 349 | 10 | N/A | 79 | N/A |
| 3/31/2017 | 353 | 18 | N/A | 72 | N/A |
| 12/31/2016 | 376 | 29 | N/A | 78 | N/A |
| 9/30/2016 | 389 | 42 | N/A | 87 | N/A |
| 6/30/2016 | 388 | 48 | N/A | 102 | N/A |
| 3/31/2016 | 404 | 66 | N/A | 83 | N/A |
| 12/31/2015 | 374 | 55 | N/A | 84 | N/A |
| 9/30/2015 | 357 | 53 | N/A | 57 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: IMAXDas prognostizierte Gewinnwachstum (21.6% pro Jahr) liegt über der Sparquote (3.7%).
Ertrag vs. Markt: IMAXDie Erträge des Unternehmens (21.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (17.4% pro Jahr).
Hohe Wachstumserträge: IMAXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: IMAXDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (13.6% pro Jahr).
Hohe Wachstumseinnahmen: IMAXDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: IMAXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16.9%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/21 19:09 |
| Aktienkurs zum Tagesende | 2026/09/18 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
IMAX Corporation wird von 20 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Marla Backer | Ascendiant Capital Markets LLC |
| David McFadgen | ATB Cormark Historical (Cormark Securities) |
| Patrick Sholl | Barrington Research Associates, Inc. |